AR004826A1 - Metodo para identificar a un paciente en riesgo de adquirir una afeccion trombotica debido a la deficiencia de factor v y un equipo de diagnostico para realizar dicho metodo. - Google Patents
Metodo para identificar a un paciente en riesgo de adquirir una afeccion trombotica debido a la deficiencia de factor v y un equipo de diagnostico para realizar dicho metodo.Info
- Publication number
- AR004826A1 AR004826A1 ARP960105444A ARP960105444A AR004826A1 AR 004826 A1 AR004826 A1 AR 004826A1 AR P960105444 A ARP960105444 A AR P960105444A AR P960105444 A ARP960105444 A AR P960105444A AR 004826 A1 AR004826 A1 AR 004826A1
- Authority
- AR
- Argentina
- Prior art keywords
- factor
- deficiency
- individuals
- apc
- reagent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96461—Protein C (3.4.21.69)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96463—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Se describe un metodo para la determinación en sangre de la Proporción del Factor V (FVR) (léaseproporción del factor cinco) y los equipos para larealización del mismo que identifican a los individuos que poseen una deficiencia genéticaes pecífica, conocida como la deficiencia del Factor V deLeiden,u otra deficiencia del Factor V genética o adquirida, que hace que tales individuos sean propensos a la tromboembolia venosa. En este análisis, secompara la actividad del Factor V deuna mu estra plasma sanguínea expuesta a la Proteína C activada (APC) con la actividad del factor V de una muestra similaren ausencia de APC, luego de que ambas muestras han sido tratadas con un agente activador. La proporción entre el nivelde activ idad del Factor V sinAPC y el nivel de actividad del Factor V con APC,identifica los individuos que se encuentran en riesgo de sufrir una afección trombótica debido a ladeficiencia del Factor V y diferencia a los individuos con unadeficiencia heteróciga de los individuos con una deficiencia homóloga. La invención tambiénse refiere a un equipo de diagnóstico para realizar dicho método caracterizado porque comprende un primer reactivo que comprende una composición fosfolípidayun activador en contacto;un segundo reactivo que comprende proteinas C activadas; un tercer reactivo que comprende plasma reducido en Factor V, y uncuarto reactivo que comprende tromboplastina con Ca++.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US781595P | 1995-11-30 | 1995-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR004826A1 true AR004826A1 (es) | 1999-03-10 |
Family
ID=21728263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP960105444A AR004826A1 (es) | 1995-11-30 | 1996-11-29 | Metodo para identificar a un paciente en riesgo de adquirir una afeccion trombotica debido a la deficiencia de factor v y un equipo de diagnostico para realizar dicho metodo. |
Country Status (12)
Country | Link |
---|---|
US (1) | US5766869A (es) |
EP (1) | EP0873418B1 (es) |
AR (1) | AR004826A1 (es) |
AT (1) | ATE254666T1 (es) |
AU (1) | AU1055697A (es) |
CA (1) | CA2238814A1 (es) |
DE (1) | DE69630808D1 (es) |
EA (1) | EA000673B1 (es) |
IL (1) | IL124662A (es) |
MX (1) | MX9804305A (es) |
PL (1) | PL327006A1 (es) |
WO (1) | WO1997020066A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU690535B2 (en) * | 1993-01-29 | 1998-04-30 | Bjorn Dahlback | Novel anticoagulant cofactor activity |
AU690644B2 (en) * | 1994-02-14 | 1998-04-30 | Rijksuniversiteit Leiden | A method for screening for the presence of a genetic defect associated with thrombosis and/or poor anticoagulant response to activated protein C |
US5708591A (en) * | 1995-02-14 | 1998-01-13 | Akzo Nobel N.V. | Method and apparatus for predicting the presence of congenital and acquired imbalances and therapeutic conditions |
US6429017B1 (en) | 1999-02-04 | 2002-08-06 | Biomerieux | Method for predicting the presence of haemostatic dysfunction in a patient sample |
US6898532B1 (en) | 1995-06-07 | 2005-05-24 | Biomerieux, Inc. | Method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample |
US6321164B1 (en) | 1995-06-07 | 2001-11-20 | Akzo Nobel N.V. | Method and apparatus for predicting the presence of an abnormal level of one or more proteins in the clotting cascade |
US6379975B1 (en) | 1996-11-27 | 2002-04-30 | T.A.C. Thrombosis And Coagulation Aktiebolag | Methods and reagents for determining protein S |
AT405692B (de) * | 1997-03-27 | 1999-10-25 | Immuno Ag | Reagens zur bestimmung der aptt |
US6502040B2 (en) | 1997-12-31 | 2002-12-31 | Biomerieux, Inc. | Method for presenting thrombosis and hemostasis assay data |
EP1147423B1 (en) | 1999-02-04 | 2004-11-10 | bioMérieux, Inc. | A method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample |
US7179612B2 (en) | 2000-06-09 | 2007-02-20 | Biomerieux, Inc. | Method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality |
US6855509B2 (en) | 2000-12-19 | 2005-02-15 | Instrumentation Laboratory Company | Protein S functional assay and kit therefor |
EP1474151A4 (en) * | 2002-01-17 | 2010-03-03 | R E D Lab N V | METHODS OF TREATING CHRONIC IMMUNE DISEASE |
US20050026168A1 (en) * | 2002-12-13 | 2005-02-03 | Genesis Group Inc. | Method for the detection of risk factors associated with myocardial infarction |
EP2360269A1 (en) * | 2005-07-28 | 2011-08-24 | American Diagnostica Inc. | Lupus anticoagulant testing |
US7932021B2 (en) * | 2005-07-28 | 2011-04-26 | American Diagnostica, Inc. | Lupus anticoagulant testing |
EP2997156B1 (en) | 2013-05-14 | 2018-04-25 | Struszym S.L. | Methods for determining coagulation factor activities |
EP3839059A1 (en) * | 2019-12-16 | 2021-06-23 | CGT Enterprises, LLC | Devices and methods for determining coagulation factor activities |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3516579A1 (de) * | 1984-11-19 | 1986-05-22 | Boehringer Mannheim Gmbh, 6800 Mannheim | Gerinnungstest auf teststreifen |
US4948724A (en) * | 1985-09-05 | 1990-08-14 | Yin E Thye | Composition, kit and method for assaying heparin and a method for making the composition |
US5472850A (en) * | 1991-04-10 | 1995-12-05 | Oklahoma Medical Research Foundation | Quantitative clotting assay for activated factor VII |
US5051357A (en) * | 1989-07-14 | 1991-09-24 | Board Of Trustees Operating Michigan State University | Method and assay using inactivation of factors Va and VIIIa by activated Protein C to diagnose thrombic disease or assay for Protein C and kit therefor |
SE464135B (sv) * | 1989-07-14 | 1991-03-11 | Kabivitrum Ab | Foerfarande foer bestaemning av funktionell aktivitet av fritt protein s eller protein c i ett plasmaprov |
US5169786A (en) * | 1989-12-19 | 1992-12-08 | Ortho Diagnostic Systems, Inc. | Method of determining levels of extrinsic and intrinsic clotting factors and protein c |
WO1993007491A1 (en) * | 1991-10-04 | 1993-04-15 | Board Of Regents Of The University Of Nebraska | A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins |
SE470274B (sv) * | 1991-11-13 | 1993-12-20 | Bjoern Dahlbaeck | Användning av en in vitro-metod för diagnos av blodkoagulationssjukdomar |
EP0585504A1 (en) * | 1992-09-04 | 1994-03-09 | Pentapharm A.G. | Phospholipid dependant prothrombin activator and its use in lupus anticoagulant testing |
AU690535B2 (en) * | 1993-01-29 | 1998-04-30 | Bjorn Dahlback | Novel anticoagulant cofactor activity |
US5472852A (en) * | 1993-09-15 | 1995-12-05 | Oklahoma Medical Research Foundation | Assay for detection of selective Protein C inhibition by patients |
AU690644B2 (en) * | 1994-02-14 | 1998-04-30 | Rijksuniversiteit Leiden | A method for screening for the presence of a genetic defect associated with thrombosis and/or poor anticoagulant response to activated protein C |
US5418141A (en) * | 1994-05-06 | 1995-05-23 | Avocet Medical, Inc. | Test articles for performing dry reagent prothrombin time assays |
US5705395A (en) * | 1994-11-14 | 1998-01-06 | The Scripps Research Institute | Method for diagnosis of thrombotic disorders |
-
1996
- 1996-11-27 US US08/757,926 patent/US5766869A/en not_active Expired - Fee Related
- 1996-11-29 IL IL12466296A patent/IL124662A/xx not_active IP Right Cessation
- 1996-11-29 PL PL96327006A patent/PL327006A1/xx unknown
- 1996-11-29 AT AT96941403T patent/ATE254666T1/de not_active IP Right Cessation
- 1996-11-29 CA CA002238814A patent/CA2238814A1/en not_active Abandoned
- 1996-11-29 DE DE69630808T patent/DE69630808D1/de not_active Expired - Lifetime
- 1996-11-29 AU AU10556/97A patent/AU1055697A/en not_active Abandoned
- 1996-11-29 AR ARP960105444A patent/AR004826A1/es unknown
- 1996-11-29 EP EP96941403A patent/EP0873418B1/en not_active Revoked
- 1996-11-29 WO PCT/US1996/018560 patent/WO1997020066A1/en not_active Application Discontinuation
- 1996-11-29 EA EA199800493A patent/EA000673B1/ru not_active IP Right Cessation
-
1998
- 1998-05-29 MX MX9804305A patent/MX9804305A/es unknown
Also Published As
Publication number | Publication date |
---|---|
DE69630808D1 (de) | 2003-12-24 |
IL124662A0 (en) | 1998-12-06 |
EA000673B1 (ru) | 2000-02-28 |
EA199800493A1 (ru) | 1998-12-24 |
US5766869A (en) | 1998-06-16 |
WO1997020066A1 (en) | 1997-06-05 |
CA2238814A1 (en) | 1997-06-05 |
ATE254666T1 (de) | 2003-12-15 |
EP0873418A1 (en) | 1998-10-28 |
IL124662A (en) | 2000-08-13 |
PL327006A1 (en) | 1998-11-09 |
MX9804305A (es) | 1998-11-30 |
EP0873418B1 (en) | 2003-11-19 |
AU1055697A (en) | 1997-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR004826A1 (es) | Metodo para identificar a un paciente en riesgo de adquirir una afeccion trombotica debido a la deficiencia de factor v y un equipo de diagnostico para realizar dicho metodo. | |
Sugawara et al. | Lipid peroxidation and concentration of glutathione in erythrocytes from workers exposed to lead. | |
Canakci et al. | Increased levels of 8-hydroxydeoxyguanosine and malondialdehyde and its relationship with antioxidant enzymes in saliva of periodontitis patients | |
Liu et al. | Molecular defect of the band 3 protein in southeast Asian ovalocytosis | |
Jaiswal et al. | Human sperm chemotaxis: is progesterone a chemoattractant? | |
Depinho et al. | The Hermansky–Pudlak syndrome: report of three cases and review of pathophysiology and management considerations | |
Wolfe et al. | Molecular defect in the membrane skeleton of blood bank-stored red cells. Abnormal spectrin-protein 4.1-actin complex formation. | |
Zalata et al. | White blood cells cause oxidative damage to the fatty acid composition of phospholipids of human spermatozoa | |
Moor et al. | Haemostatic factors and inhibitors and coronary artery bypass grafting: preoperative alterations and relations to graft occlusion | |
Tavilani et al. | Relationship between seminal antioxidant enzymes and the phospholipid and fatty acid composition of spermatozoa | |
Wegner et al. | Evaluation of para oxonase 1 arylesterase activity and lipid peroxide levels in patients with type 1 diabetes | |
Cesco et al. | Levels of aspartate aminotransferase (AST) in saliva of patients with different periodontal conditions | |
Nabatchican et al. | Relationship between prooxidant-antioxidant balance and severity of coronary artery disease in patients of Imam Khomeini Hospital of Tehran, Iran | |
Millican et al. | Glucose-modified low density lipoprotein enhances human monocyte chemotaxis | |
Denis et al. | Electrophoretic characterization of the prostate: I. Proteins and lactic dehydrogenase in benign hyperplasia and carcinoma | |
EP0406971B1 (en) | Method and kit for determining the functional activity of protein S in human plasma | |
Lindberg et al. | Serum sialic acid and its correlates in community samples from Akita, Japan and Minneapolis, USA. | |
Ittyerah et al. | Coagulation factor XIII concentration in sickle-cell disease | |
Freeman et al. | Fetal corticotrophin-releasing hormone mRNA, but not phosphatidylserine-exposing microparticles, in maternal plasma are associated with factor VII activity in pre-eclampsia | |
Peabody et al. | Altered endogenous fibrinolysis and biochemical factors in atherosclerosis | |
ATE5749T1 (de) | Verfahren und diagnostisches mittel zur direkten bestimmung des lipidgehaltes der betalipoproteine des blutes. | |
Karai et al. | Alterations of lipids of the erythrocyte membranes in workers exposed to lead | |
US4168203A (en) | Quantitative analysis of neutral lipids and lecithin | |
Kunihiko et al. | Effects of albumin and other proteins during assay of amylase activity | |
Weaver et al. | Aged amylase: a valuable test for detecting and tracking pancreatic pseudocysts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |